Population pharmacokinetics and bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation

Clinical Pharmacokinetics

Volumn 49, Issue 10, 2010, Pages 683-692

  Benkali, Khaled ^a   Rostaing, Lionel ^b,c   Premaud, Aurélie ^a   Woillard, Jean Baptiste ^a   Saint Marcoux, Franck ^a   Urien, Saik ^d   Kamar, Nassim ^b,e   Marquet, Pierre ^a   Rousseau, Annick ^a,f  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c CHU PURPAN   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e CHU RANGUEIL   (France)

^f UNIVERSITY OF LIMOGES   (France)

Author keywords

Controlled release drugs; Immunosuppressants; Pharmacokinetic modelling; pharmacokinetics; Pharmacokinetics; Population pharmacokinetics; Renal transplant; Tacrolimus

Indexed keywords

CREATININE; CYCLOSPORIN; CYTOCHROME P450 3A5; EPSILON GLOBIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG FORMULATION; DRUG RELEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY GRAFT REJECTION; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; AREA UNDER CURVE; BAYES THEOREM; CYTOCHROME P-450 ENZYME SYSTEM; DELAYED-ACTION PREPARATIONS; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS;

EID: 77956374555     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11535950-000000000-00000     Document Type: Article

References (28)

1. Weng FL, Israni AK, Joffe MM, et al. Race and electronically measured ad-herence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol 2005 Jun; 16 (6): 1839-1848
2. Silva HT. Tacrolimus once-daily formulation in the prophylaxis of transplant rejection in renal or liver allograft recipients: a viewpoint by Helio Tedesco Silva Jr. Drugs 2007; 67 (13): 1944-1945
3. Silva Jr HT, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007 Mar; 7 (3): 595-608
4. Undre NA. Use of a once daily modified release tacrolimus regimen in de novo liver transplant recipients [abstract]. Am J Transplant 2005; 5 (s11): 374
5. Undre NA. Use of a once daily modified release tacrolimus regimen in de novo kidney transplant recipients [abstract]. Am J Transplant 2005; 5 (s11): 190
6. Alloway R, Steinberg S, Khalil K, et al. Conversion of stable kidney trans-plant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc 2005 Mar;37 (2): 867-870 (Pubitemid 40590728)
7. Alloway R, Steinberg S, Khalil K, et al. Two years postconversion from a Prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation 2007 Jun 27; 83 (12): 1648-1651 (Pubitemid 46987920)
8. Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver trans-plant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc 2005 Mar;37 (2): 1211-1213 (Pubitemid 40590839)
9. Heffron TG, Pescovitz MD, Florman S, et al. Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. Am J Transplant 2007 Jun; 7 (6): 1609-1615
10. Heffron TG. A two year follow-up of stable pediatric liver transplant reci-pients converted from a twice daily Prograf based regimen to a once daily extended release tacrolimus based regimen [abstract]. Am J Transplant 2007; 7 (s2): 348
11. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmaco-kinetics of tacrolimus. Clin Pharmacokinet 1995 Dec; 29 (6): 404-430
12. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European Consensus Conference. Ther Drug Monit 2009 Apr; 31 (2): 139-152
13. Crespo M, Mir M, Marin M, et al. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. Transplant Proc 2009 Jul; 41 (6): 2115-2117
14. Mourad M, Wallemacq P, De MM, et al. The influence of genetic poly-morphisms of cytochrome P450 3A5 and ABCB1 on starting dose-and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function. Clin Chem Lab Med 2006; 44 (10): 1192-1198
15. Press RR, Ploeger BA, den Hartigh J, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit 2009 Apr; 31 (2): 187-197
16. Quteineh L, Verstuyft C, Furlan V, et al. Influence of CYP3A5 genetic poly-morphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol 2008 Dec; 103 (6): 546-552
17. Benkali K, Premaud A, Picard N, et al. Tacrolimus population pharmaco-kinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet 2009; 48 (12): 805-816
18. Saint-Marcoux F, Knoop C, Debord J, et al. Pharmacokinetic study of tacro-limus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. Clin Phar-macokinet 2005; 44 (12): 1317-1328
19. Le MY, Djebli N, Szelag JC, et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 2006 Jul; 80 (1): 51-60
20. Boekmann AJ, Sheiner LB, Beal SL. NONMEM user's guide: part V. Intro-ductory guide. San Francisco (CA): University of California, 1992
21. Rousseau A, Leger F, Le MY, et al. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmaco-kinetic models and design of a Bayesian estimator. Ther Drug Monit 2004 Feb; 26 (1): 23-30
22. Urien S. R for NONMEM. A graphical interface for NONMEM outputs-2009 [online]. Available from URL: https://sourceforge. net/project/showfiles. php?group-id=29501&package-id=140129&release-id=538680 [Accessed 2010 Jul 26]
23. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999 Apr; 59 (1): 19-29
24. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981 Aug; 9 (4): 503-512
25. Rousseau A, Marquet P. Modelling ciclosporin double-peak absorption profiles in the early post-transplantation period. Clin Pharmacokinet 2004; 43 (14): 1055-1057
26. Staatz CE, Willis C, Taylor PJ, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002 Dec; 72(6): 660-669
27. Undre NA, Stevenson P, Schafer A. Pharmacokinetics of tacrolimus: clinically relevant aspects. Transplant Proc 1999 Nov; 31 (7A): 21S-4S
28. Venkataramanan R, Shaw LM, Sarkozi L, et al. Clinical utility of monitoring tacrolimus blood concentrationsinlivertransplant patients. J Clin Pharmacol 2001 May; 41 (5): 542-551